A practical reference on Drug affinity complex: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-15 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
=== Research in Utah === Research in the Kopeček Biomedical Polymers Laboratory focuses on: a) Macromolecular therapeutics with emphasis on combination chemotherapy and immunotherapy; b) Macromolecular therapeutics for brain delivery; c) Drug-free macromolecular therapeutics – a new paradigm in nanomedicine where apoptosis is initiated by biorecognition of nanoconjugates at the cell surface and receptor crosslinking; no low molecular weight drug is needed.
Once the substrate is bound and oriented to the active site, catalysis can begin. The residues of the catalytic site are typically very close to the binding site, and some residues can have dual-roles in both binding and catalysis. Catalytic residues of the site interact with the substrate to lower the activation energy of a reaction and thereby make it proceed faster. They do this by a number of different mechanisms including the approximation of the reactants, nucleophilic/electrophilic catalysis and acid/base catalysis. These mechanisms will be explained below.
In November 2016, India's Drug Consultative Committee announced it was embarking on establishing a definition of drugs which could be dispensed without a prescription. Prior to this, the general assumption was that any drug which did not fall into a prescription schedule could be purchased without a prescription. However, the needed definition had not been enacted by early 2018. The lack of a legal definition for OTC drugs has led to this US$4 billion market segment being effectively unregulated. In the Netherlands, there are four categories:
Sources: en.wikipedia.org
=== Audiobook === An audiobook version of Ubik was released in 2008 by Blackstone Audio. The audiobook, read by Anthony Heald, is unabridged and runs approximately 7 hours over 6 CDs. Another version released in 2016 by Brilliance Audio, read by Luke Daniels, is unabridged and runs 7 hrs 56 minutes.
=== Plant breeding === Selective breeding of cannabis plants has expanded and diversified as commercial and therapeutic markets develop. Some growers in the US succeeded in lowering the proportion of CBD-to-THC to accommodate customers who preferred varietals that were more mind-altering due to the higher THC and lower CBD content. In the US, hemp is classified by the federal government as cannabis containing no more than 0.3% THC by dry weight. This classification was established in the 2018 Farm Bill and was refined to include hemp-sourced extracts, cannabinoids, and derivatives in the definition of hemp.
In 1947, Howard Hughes redirected the Hughes Aircraft Company's efforts from airplanes to helicopters. The effort began in earnest in 1948, when helicopter manufacturer Kellett Autogiro Corporation sold their latest design to Hughes for production. The XH-17 "Sky Crane" first flew in October 1952, but was commercially unsuccessful. In 1955 the company began building light helicopters when Howard Hughes split the helicopter production unit from the Hughes Aircraft Co., and reconstituted it with the Hughes Tool Co. as the Hughes Tool Co. Aircraft Division, with a focus on the production of light helicopters. The Hughes Model 269 was the company's first successful helicopter design. Built in 1956, and entering production in 1957, it served to capture a large portion of the commercial market for Hughes. It would eventually become part of the Army inventory as a primary trainer (TH-55 Osage). In May 1965, the company won the contract for a new observation helicopter for the U.S. Army, and produced the OH-6 Cayuse (Hughes Model 369). The OH-6 was later developed into the civilian Model 500, variants of which remain in production to this day.
== See also == Jaundice Liver function tests Lipoprotein-X – an abnormal low density lipoprotein found in cholestasis Intrahepatic cholestasis of pregnancy Progressive familial intrahepatic cholestasis Feathery degeneration – a histopathologic finding associated with cholestasis
Sources: en.wikipedia.org
is the number of amino acid residues, R1 is the first residue of the protein P, R2 is the second residue, and so forth. The problem with this approach was that in some sequence-similarity-search-based tools, the query protein often lacked significant homology (or sequence similarity) with any other known protein in the database. To resolve this problem, discrete models for representing protein samples were proposed. The simplest discrete model is using the amino acid composition (AAC) to represent protein samples. Under the AAC model, the protein P of Eq.1 can also be expressed by
=== Pharmacodynamics === Diazoxide acts as a ATP-sensitive potassium channel (KATP) opener. It has been found to act as a positive allosteric modulator of the ionotropic glutamate AMPA and kainate receptors.
The gameplay involves capturing or defending Hybrid NPCs across four maps, incorporating mechanics inspired by Counter-Strike and Vampire Slayer. Vampire Slayer – is a teamplay mod where two sides: vampires and slayers, battle it out in a variety of atmospheric settings. Planet Half-Life called the original release "A great mod". They also reviewed Chapter IV and wrote: "The new maps fit perfectly with the atmosphere built up from the previous releases." PC Zone gave version 1.1 a rating of three out of five, Chapter III a rating of 69%, and Chapter V a rating of 91%. War in Europe – A World War II-themed mod released in 1999 that includes deathmatch, team deathmatch, and capture the flag. The player earns "promotions" by fragging, which allows purchasing of additional weapons. If the player takes a hit, they will start to bleed, which can be treated with a medkit. PC Gameplay reviewed the game in 2001 and gave a rating of six out of ten, calling it worse than Day of Defeat. Wasteland Half-Life – A post-apocalyptic-themed mod with modes for deathmatch, team deathmatch, and objective capture. PC Zone gave it a score of four out of five and said it's not as popular as it deserves to be. .NetGamer said that despite the familiar gameplay, the mod has a top-notch technical execution. They also praised the maps and the character models. Later, an updated version of the mod was released, titled The Wastes. PC Zone gave it a score 69 out of 100 and called it a worthwhile update.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.